CareDx, Inc. (CDNA): Price and Financial Metrics


CareDx, Inc. (CDNA): $22.41

0.93 (+4.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CDNA POWR Grades


  • Value is the dimension where CDNA ranks best; there it ranks ahead of 63.54% of US stocks.
  • CDNA's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • CDNA's current lowest rank is in the Momentum metric (where it is better than 5.5% of US stocks).

CDNA Stock Summary

  • The ratio of debt to operating expenses for CareDx Inc is higher than it is for about merely 12.54% of US stocks.
  • CDNA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 11.95% of US stocks.
  • The volatility of CareDx Inc's share price is greater than that of 87.88% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CDNA, based on their financial statements, market capitalization, and price volatility, are NTRA, ESTC, PTE, ASTC, and ASAN.
  • Visit CDNA's SEC page to see the company's official filings. To visit the company's web site, go to www.caredx.com.

CDNA Valuation Summary

  • In comparison to the median Healthcare stock, CDNA's price/sales ratio is 33.92% higher, now standing at 15.2.
  • CDNA's price/sales ratio has moved up 10.9 over the prior 87 months.
  • CDNA's price/sales ratio has moved up 10.9 over the prior 87 months.

Below are key valuation metrics over time for CDNA.

Stock Date P/S P/B P/E EV/EBIT
CDNA 2021-08-31 15.2 8.0 -431.0 -354.3
CDNA 2021-08-30 16.7 8.8 -473.6 -392.4
CDNA 2021-08-27 16.6 8.8 -469.6 -388.8
CDNA 2021-08-26 16.0 8.5 -454.2 -375.1
CDNA 2021-08-25 16.0 8.5 -454.1 -375.0
CDNA 2021-08-24 16.2 8.6 -459.0 -379.3

CDNA Growth Metrics

    Its 5 year price growth rate is now at 523.59%.
  • The 3 year price growth rate now stands at 616.22%.
  • Its year over year price growth rate is now at 188.34%.
CDNA's revenue has moved up $268,907,000 over the prior 70 months.

The table below shows CDNA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 296.397 -19.294 -30.662
2021-09-30 275.821 -16.279 -18.026
2021-06-30 253.601 -11.454 -8.947
2021-03-31 221.214 2.856 -13.578
2020-12-31 192.194 33.431 -18.714
2020-09-30 169.371 25.167 -19.976

CDNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDNA has a Quality Grade of C, ranking ahead of 63.01% of graded US stocks.
  • CDNA's asset turnover comes in at 0.543 -- ranking 49th of 81 Healthcare stocks.
  • MGLN, OPGN, and LH are the stocks whose asset turnover ratios are most correlated with CDNA.

The table below shows CDNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.543 0.676 -0.174
2021-06-30 0.557 0.680 -0.105
2021-03-31 0.550 0.673 -0.201
2020-12-31 0.628 0.672 -0.382
2020-09-30 0.673 0.664 -0.802
2020-06-30 0.751 0.655 -1.009

CDNA Price Target

For more insight on analysts targets of CDNA, see our CDNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $107.33 Average Broker Recommendation 1.36 (Strong Buy)

CDNA Stock Price Chart Interactive Chart >

Price chart for CDNA

CDNA Price/Volume Stats

Current price $22.41 52-week high $92.55
Prev. close $21.48 52-week low $19.34
Day low $21.40 Volume 618,400
Day high $22.52 Avg. volume 817,234
50-day MA $25.34 Dividend yield N/A
200-day MA $41.02 Market Cap 1.19B

CareDx, Inc. (CDNA) Company Bio


CareDx, Inc. focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is based in Brisbane, California.


CDNA Latest News Stream


Event/Time News Detail
Loading, please wait...

CDNA Latest Social Stream


Loading social stream, please wait...

View Full CDNA Social Stream

Latest CDNA News From Around the Web

Below are the latest news stories about CareDx Inc that investors may wish to consider to help them evaluate CDNA as an investment opportunity.

CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript

CareDx, Inc (CDNA) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Ian Cooney - Vice President of Investor Relations Reg Seeto - President & Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Dipesh Patel -...

SA Transcripts on Seeking Alpha | February 25, 2022

CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

CareDx Reports Fourth Quarter and Full Year 2021 Results

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights: Achieved total revenue of $79.2 million for the three months ended December 31, 2021, increasing 35% ove

Yahoo | February 24, 2022

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World''s First Successful Living Xenotransplantation

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world''s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022. Surgeons from the University of Maryland School of Medicine (UMSOM) are using adapted versions of two complementary, non-invasive CareDx surveillance solutions, experimentally, t...

Benzinga | February 22, 2022

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring Worlds First Successful Living Xenotransplantation

CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health

GlobeNewswire | February 22, 2022

Read More 'CDNA' Stories Here

CDNA Price Returns

1-mo -13.61%
3-mo -43.58%
6-mo -51.41%
1-year -75.10%
3-year -38.25%
5-year 1,937.27%
YTD -50.73%
2021 -37.23%
2020 235.88%
2019 -14.20%
2018 242.51%
2017 171.85%

Continue Researching CDNA

Want to see what other sources are saying about CareDx Inc's financials and stock price? Try the links below:

CareDx Inc (CDNA) Stock Price | Nasdaq
CareDx Inc (CDNA) Stock Quote, History and News - Yahoo Finance
CareDx Inc (CDNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5121 seconds.